A single dose of erythropoietin in ST-elevation myocardial infarction

Adriaan A. Voors, Anne M S Belonje, Felix Zijlstra, Hans L. Hillege, Stefan D. Anker, Riemer H J A Slart, René A. Tio, Arnoud Van 'T Hof, J. Wouter Jukema, Hans Otto J Peels, José P S Henriques, Jurriën M. Ten Berg, Jeroen Vos, Wiek H. Van Gilst, Dirk J. Van Veldhuisen

Research output: Contribution to journalArticlepeer-review

Abstract

Aims Cardioprotective effects of erythropoietin (EPO) have been shown in experimental and smaller clinical studies. We performed a prospective, multicentre, randomized trial to assess the effects of a single high dose of EPO after primary coronary intervention (PCI) for an ST-elevation myocardial infarction (STEMI). Methods and resultsPatients with a successful PCI for a first STEMI were randomized to receive either standard medical care alone, or in combination with a single bolus with 60 000IU i.v. of epoetin alfa within 3 h after PCI. Primary endpoint was left ventricular ejection fraction (LVEF) after 6 weeks, assessed by planar radionuclide ventriculography. Pre-specified secondary endpoints included enzymatic infarct size and major adverse cardiovascular events.A total of 529 patients were enrolled (EPO n = 263, control n = 266). At baseline (before EPO administration), groups were well-matched for all relevant characteristics. After a mean of 6.5 (±2.0) weeks, LVEF was 0.53 (±0.10) in the EPO group and 0.52 (±0.11) in the control group (P = 0.41). Median area under the curve (inter-quartile range) after 72 h for creatinine kinase was 50 136 (28 212-76 664)U/L per 72 h in the EPO group and 53 510 (33 973-90 486)U/L per 72 h in the control group (P = 0.058). More major adverse cardiac events occurred in the control than in the EPO group (19 vs. 8; P = 0.032). Conclusion A single high dose of EPO after a successful PCI for a STEMI did not improve LVEF after 6 weeks. However, the use of EPO was related to less major adverse cardiovascular events and a favourable clinical safety profile. Clinical Trial Registration Information: NCT00449488; http://www.clinicaltrials.gov/ct2/show/NCT00449488?term=voors&rank=2.

Original languageEnglish
Pages (from-to)2593-2600
Number of pages8
JournalEuropean Heart Journal
Volume31
Issue number21
DOIs
Publication statusPublished - Nov 2010

Keywords

  • Cardiovascular events
  • Erythropoietin
  • Infarct size
  • Left ventricular function
  • ST-elevation myocardial infarction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'A single dose of erythropoietin in ST-elevation myocardial infarction'. Together they form a unique fingerprint.

Cite this